

What: Finance Committee Meeting
 Date & Time: Thursday, March 02, 2023; 11:00-12:00 p.m. (PT)
 Location: Webinar/Teleconference
 Zoom Link: To register for the meeting, please review the [Public Comment Protocol](#) then email wvameetings@wavaccine.org at least two business days in advance of the meeting.

Notice: Meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes of the meeting are approved.

Approx. Time	Pg.		Topic / Anticipated Action	Presented by:
11:00-11:05 a.m.			1. Welcome & Introductions a. Notification of Recording	R. Parker
11:05-11:10 a.m.	Pg. 3-4	*	2. Calendar Consent Items a. Finance Committee Minutes, September 22, 2022	R. Parker
11:10-11:20 a.m.	Pg. 5-21	*	3. Financial Update a. FYTD January 2023 Unaudited Financial Statements b. Cash Discussion	J. Zell / P. Miller / L. Walker
11:20-11:45 a.m.	Pg. 22-37	*	4. FY24 Administrative Budget and Assessment Grid a. Initial Assumptions Discussion b. Reserves Discussion c. Budget Review	J. Zell / P. Miller / L. Walker
11:45-11:50 a.m.			5. Annual Auditor Engagement	J. Zell
11:50-11:55 a.m.			6. Other Matters from Committee Members	Any
12:00 p.m.			7. Closing	R. Parker

* Indicates agenda item attached

**Washington Vaccine Association
Finance Committee Meeting
September 22, 2022; 11:00 a.m.-12:00 p.m. (PT)**

Attendance. This meeting was conducted solely by webinar. Participating in all or part of the meeting were the following individuals:

<u>Directors</u>	<u>Helms & Company, Inc.</u>
Randy Parker, Northwest Carpenters Trusts, Chair	Patrick Miller, MPH, WVA, Administrative
Jason Farber, Davis Wright Tremaine LLP	Director
John Sobeck, MD, Regence and Asuris	Ashley Ithal, MPH, WVA, Program Support
<u>WVA</u>	Leslie Walker, CPA, Mason+Rich, PA
Julia G. Zell, MA., Esq., Executive Director	<u>Others</u>
	Allen D. Gilbert, CliftonLarsonAllen LLP
	David Keller, Morgan Stanley
	Polly Sidwell, Morgan Stanley

I. Summary of Actions Taken and/or Recommended

Actions Taken

- i. To approve the minutes of the April 7, 2022 Finance Committee meeting.
- ii. To recommend the adoption and publication of the 2021/2022 audited financials and auditor's letter.

II. Welcome and Introductions

Welcome and Introductions

Mr. Parker called the meeting to order at 11:05 a.m. Ms. Zell gave a notice of recording for the sole purpose of creating the minutes.

III. Calendar Consent Items

Mr. Parker directed the Committee's attention to the draft minutes submitted for approval. There being no questions or comments, Mr. Parker asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously

VOTED: To approve the minutes of the April 7, 2022 Finance Committee minutes.

IV. Financial Update

2021/2022 Audited Financials

Mr. Gilbert provided an overview of the 2021/2022 Audit Report including a review of the Governance Letter. Mr. Gilbert reported that no audit adjustments were needed during the financial statement audit, no material weaknesses were identified in internal control letter, and no new standards or policies were implemented for FY2022. Mr. Gilbert mentioned that a new lease standard will not impact the WVA. Mr. Gilbert noted that the resulting opinion from the audit report was positive for the organization. Finally, Mr. Gilbert discussed a new component of the audit this year whereby the WVA's investment portfolio was analyzed by Harvest Investments. The Harvest report had slight differences in bond valuations, but that was not of concern given the size of the portfolio.

There being no questions or comments, Mr. Parker asked for a motion to recommend adoption and publication of the 2021/2022 audited financial statements and the auditor's letter. Upon motion duly made and seconded, it was unanimously

VOTED: To recommend the adoption and publication of the 2021/2022 audited financials and auditor's letter.

Mr. Gilbert to send the final documents dated September 22, 2022 to Ms. Zell. Mr. Miller will post them to the website

Investment Portfolio

Ms. Zell invited Ms. Sidwell and Mr. Keller to provide a financial update. Ms. Sidwell reported that Morgan Stanley uses Clearwater Analytics, an independent entity, to test the WVA portfolio every evening against the WVA investment policy statement. Mr. Keller provided an overview of the overall WVA investment portfolio. There was discussion regarding the rising interest rates, investment opportunities for the WVA, and a reimplementing a short-term cash management strategy between Morgan Stanley and KeyBank.

Unaudited Financial Statements

Mr. Miller reviewed the financial statements for the first two months of the fiscal year. He highlighted that the WVA has seen a continued trend for the last four months of remittances exceeding collections which has been helping to drive the total cash reserves down as planned. Mr. Miller reviewed the administrative budget and stated that a revised version of the financial statements will be sent out to the Committee.

A discussion was held regarding pending changes being made effective January 2023 by the WA Department of Health (DOH) to the fund source split. The DOH has proposed the WVA's proportion increases to 49% based upon two sets of projections. Ms. Zell provided an overview of the fund source split and how it impacts the WVA. She stated that the DOH has been very transparent and inclusive in the process, and that we are expecting a draft set of projections shortly for review prior to the final projections.


V. Closing

With no further business before the Committee, Mr. Parker concluded the meeting at 11:58 a.m.


WASHINGTON VACCINE ASSOCIATION
UNAUDITED FINANCIAL STATEMENTS
FOR THE SEVEN MONTHS ENDED
January 31, 2023
With Supplemental Informational Reporting

Prepared by
Helms & Company, Inc., Administrator


Cash Balances Beginning and End of Period January 2022 - January 2023



Total Vaccine Collections and Vaccine Remittances to State of WA January 2023 - January 2023



Investment Income / (Loss) January 2022 - January 2023



Washington Vaccine Association
Statement of Cash Flows
For the Periods Ended

	AH	AI	AJ	AK	AL	AM	AN	AO	AP	AQ	AQ	AQ	AQ	AQ
	Month 1/31/2022	Month 2/28/2022	Month 3/31/2022	Month 4/30/2022	Month 5/31/2022	Month 6/30/2022	Month 7/31/2022	Month 8/31/2022	Month 9/30/2022	Month 10/31/2022	Month 11/30/2022	Month 12/31/2022	Month 1/31/2023	13 Month Average
1 Cash balance - beginning	\$ 57,892,443	\$ 56,794,955	\$ 56,901,662	\$ 57,228,006	\$ 56,731,278	\$ 55,963,525	\$ 54,966,739	\$ 51,225,722	\$ 49,802,160	\$ 45,521,419	\$ 45,226,880	\$ 47,391,252	\$ 49,581,422	52,709,804.87
Inflows:														
2 Vaccine collections	4,758,484	5,567,703	7,165,492	5,855,575	5,295,645	6,203,839	5,293,104	7,684,870	7,154,302	6,593,300	7,182,396	7,262,565	5,077,451	6,238,055.81
3 Interest income - payers	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4 Investment income/ (loss)	(343,834)	(263,415)	(603,741)	(319,989)	156,297	(213,108)	181,120	(300,938)	(522,104)	(80,250)	292,475	159,984	299,489	(119,847.23)
5 Total inflows	4,414,650	5,304,288	6,561,751	5,535,586	5,451,942	5,990,731	5,474,224	7,383,932	6,632,198	6,513,050	7,474,871	7,422,549	5,376,940	\$ 6,118,209
Outflows:														
Program														
6 Vaccine remittance State of WA	(5,409,431)	(5,037,313)	(6,117,841)	(5,891,576)	(6,102,649)	(6,839,636)	(9,100,501)	(8,625,865)	(10,771,706)	(6,666,286)	(5,171,147)	(5,116,478)	(6,069,523)	(6,582,696.97)
Administration														
7 Direct Processing Costs	(76,802)	(71,898)	(71,381)	(74,821)	(74,116)	(79,377)	(84,627)	(87,483)	(83,479)	(88,260)	(100,373)	(73,539)	(95,734)	(81,683.77)
8 Executive Director Costs and Support Fees	-	(70,227)	(23,646)	(20,142)	(22,606)	(22,335)	(21,938)	(22,007)	(24,988)	(28,476)	(24,102)	(28,179)	(22,890)	(28,553.80)
9 Provider and Payer Education and Outreach	-	-	-	-	-	-	-	-	-	-	(7,279)	(597)	(40)	(608.89)
10 Administrative Costs	(20,656)	(12,893)	(10,489)	(32,125)	(11,475)	(15,318)	(4,575)	(63,139)	(29,166)	(20,967)	(3,998)	(9,986)	(21,334)	(19,701.61)
11 Other Discretionary Expenditures	(5,250)	(5,250)	(12,050)	(13,650)	(8,850)	(30,850)	(3,600)	(9,000)	(3,600)	(3,600)	(3,600)	(3,601)	(3,600)	(8,192.38)
12 Total Administration	(102,708)	(160,268)	(117,566)	(140,738)	(117,047)	(147,880)	(114,740)	(181,629)	(141,233)	(141,303)	(139,352)	(115,901)	(143,598)	(138,740)
13 Net all other outflows	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14 Total outflows	(5,512,139)	(5,197,581)	(6,235,407)	(6,032,314)	(6,219,696)	(6,987,516)	(9,215,241)	(8,807,494)	(10,912,939)	(6,807,589)	(5,310,499)	(5,232,379)	(6,213,121)	(6,721,437.42)
15 Net Cash Incr (decr) for period	(1,097,489)	106,707	326,344	(496,728)	(767,754)	(996,785)	(3,741,017)	(1,423,562)	(4,280,741)	(294,539)	2,164,372	2,190,170	(836,181)	(603,229)
16 Cash balance - end of period	\$ 56,794,955	\$ 56,901,662	\$ 57,228,006	\$ 56,731,278	\$ 55,963,525	\$ 54,966,739	\$ 51,225,722	\$ 49,802,160	\$ 45,521,419	\$ 45,226,880	\$ 47,391,252	\$ 49,581,422	\$ 48,745,241	\$ 52,106,576

Note: Cash balance includes amounts in KeyBank and Morgan Stanley

Washington Vaccine Association
Statement of Financial Position
As of January 31, 2023

ASSETS

1	Current Assets		
2	Cash and Cash Equivalents	\$	334,413
3	Accounts Receivable		-
4	Investments		48,410,828
5	Members Estimated Collectible Assessments		5,349,043
6	Prepaid Vaccine		6,022,706
7	Prepaid Administrative Services		-
8	Total Current Assets		<u>60,116,990</u>
9	Total Assets	\$	<u><u>60,116,990</u></u>

LIABILITIES AND NET ASSETS

10	Current Liabilities		
11	Accounts Payable	\$	123,958
12	Other Accruals		88,494
13	Total Current Liabilities		<u>212,452</u>
14	Assessments Collected in Excess of Vaccine Funding and Administrative Activities		<u>59,904,538</u>
15	Total Liabilities		<u>60,116,990</u>
16	Total Liabilities and Net Assets	\$	<u><u>60,116,990</u></u>

**Washington Vaccine Association
Statement of Activities and Changes in Net Assets**

		A	B	C	D	E	F
		Month Ended January 31, 2023			For Seven Months Ended January 31, 2023		
		Administrative	Vaccine	Total	Administrative	Vaccine	Total
		Revenues / Vaccine Expenses					
1	Assessment Activity:						
2	Assessments	\$ (649,232)	\$ 5,745,637	\$ 5,096,406	\$ (4,561,833)	\$ 50,733,264	\$ 46,171,431
3	Recoveries	-	-	-	351,325	-	351,325
4	Estimated Over (Under) Collections	-	-	-	-	-	-
5	Refunds	(13,123)	-	(13,123)	(184,180)	-	(184,180)
6	Estimated 2% Waste	(23,262)	-	(23,262)	(321,003)	-	(321,003)
7	Estimated Price Variance and 3% Denial	(32,587)	-	(32,587)	(133,215)	-	(133,215)
8	DOH Replenishment	-	(5,421,113)	(5,421,113)	-	(50,265,020)	(50,265,020)
9	Adjustment to Correct Inventory	-	-	-	-	-	-
10	DOH Cost Recovery Admin Charge	(84,517)	-	(84,517)	(579,613)	-	(579,613)
11	Interest Income on Assessments	-	-	-	-	-	-
12	Net Assessment Activity	(802,721)	324,524	(478,196)	(5,428,519)	468,244	(4,960,275)
13	Investment Activity:						
14	Interest and Dividend Income - Morgan Stanley	66,699	-	66,699	580,225	-	580,225
15	Realized Gain/(Loss) on Investments - Morgan Stanley	-	-	-	(2,118)	-	(2,118)
16	Unrealized Gain/(Loss) on Investments - Morgan Stanley	235,037	-	235,037	(540,281)	-	(540,281)
17	Investment Management Expenses	(9,904)	-	(9,904)	(72,194)	-	(72,194)
18	Interest Income - KeyBank	7,657	-	7,657	64,142	-	64,142
19	Net Investment Activity	299,489	-	299,489	29,774	-	29,774
20	Net Revenues	(503,232)	324,524	(178,708)	(5,398,744)	468,244	(4,930,500)

**Washington Vaccine Association
Statement of Activities and Changes in Net Assets**

	A	B	C	D	E	F
	Month Ended January 31, 2023			For Seven Months Ended January 31, 2023		
	Administrative	Vaccine	Total	Administrative	Vaccine	Total
	Other Expenses					
21 Administrative Expenses:						
22 Direct Processing Costs						
23 Administrator (Helms & Company, Inc.)	65,432	-	65,432	465,524	-	465,524
24 EDI /ACH Clearinghouse Maintenance (Helms & Company, Inc.)	3,750	-	3,750	52,763	-	52,763
25 Clearinghouse Intake Processing (Avality, Zelis, Etc.)	4,851	-	4,851	36,557	-	36,557
26 Lockbox and Bank Fees	5,394	-	5,394	28,957	-	28,957
27 Recovery and Compliance (Helms & Company, Inc.)	5,250	-	5,250	36,750	-	36,750
28 Lockbox Intake (OrboGraph)	11,058	-	11,058	18,750	-	18,750
29 Total Direct Processing Costs	95,734	-	95,734	639,301	-	639,301
30 Executive Director Costs and Related Support Fees						
31 Executive Director Salary	18,810	-	18,810	130,474	-	130,474
32 Payroll Taxes	1,749	-	1,749	6,347	-	6,347
33 Leased Employee per Check Fee	114	-	114	1,723	-	1,723
34 Executive Director Travel and Lodging, Education, and Other	1,700	-	1,700	31,451	-	31,451
35 Technology Support (Desktop and Telephony)	472	-	472	2,845	-	2,845
36 Total Executive Director Costs and Related Support Fees	22,846	-	22,846	172,840	-	172,840
37 Provider and Payer Education and Outreach						
38 Provider Education Materials, Development and Printing	40	-	40	11,877	-	11,877
39 Postage	-	-	-	-	-	-
40 Website and Information Technology	-	-	-	-	-	-
41 Technical Consultants	-	-	-	275	-	275
42 Provider Office Training Sessions	-	-	-	-	-	-
43 Advertising and Sponsorships	-	-	-	-	-	-
44 Hospitality	-	-	-	-	-	-
45 Provider Services Rep	-	-	-	264	-	264
46 Leased Employee per Check Fee	-	-	-	-	-	-
47 Total Provider and Payer Education and Outreach	40	-	40	12,416	-	12,416
48 Administrative Costs						
49 Legal Counsel	1,604	-	1,604	27,043	-	27,043
50 Audit Fees	-	-	-	23,580	-	23,580
51 Government Relations, Including Travel, Meals, and Consultants	-	-	-	-	-	-
52 Registered Agent Fee	-	-	-	-	-	-
53 Bank Fees	-	-	-	-	-	-
54 Office Supplies and Equipment	-	-	-	4,987	-	4,987
55 Rent, ELM and Storage Facility	-	-	-	-	-	-
56 Other Admin Support Provided by Lessor	-	-	-	-	-	-
57 Board Retreat and Meetings	-	-	-	-	-	-
58 Insurance						
59 Cyber Liability	19,625	-	19,625	19,625	-	19,625
60 Directors and Officers	-	-	-	52,058	-	52,058
61 General Liability	105	-	105	1,639	-	1,639
62 Insurance - Other	-	-	-	-	-	-

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

		A	B	C	D	E	F
		Month Ended January 31, 2023			For Seven Months Ended January 31, 2023		
		Administrative	Vaccine	Total	Administrative	Vaccine	Total
63	Legal - Special Projects and L	-	-	-	-	-	-
64	Total Administrative Costs	21,334	-	21,334	128,932	-	128,932
65	Other Discretionary Expenditures						
66	Executive Director and Other Contractor Bonus	-	-	-	-	-	-
67	Human Resources and Governance	3,600	-	3,600	30,601	-	30,601
68	Total Other Discretionary Expenditures	3,600	-	3,600	30,601	-	30,601
69	Total Administrative Expenses	143,555	-	143,555	984,090	-	984,090
70	Total Change in Unrestricted Net Assets	\$ (646,786)	\$ 324,524	\$ (322,262)	\$ (6,382,835)	\$ 468,244	\$ (5,914,590)

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

	A	B	C	D	E	F
	Month Ended January 31, 2023			Month Ended January 31, 2022		
	Administrative	Vaccine	Total	Administrative	Vaccine	Total
	Revenues / Vaccine Expenses					
1 Assessment Activity:						
2 Assessments	\$ (649,232)	\$ 5,745,637	\$ 5,096,406	\$ (316,833)	\$ 5,099,868	\$ 4,783,035
3 Recoveries	-	-	-	19,593	-	19,593
4 Estimated Over (Under) Collections	-	-	-	-	-	-
5 Refunds	(13,123)	-	(13,123)	(28,494)	-	(28,494)
6 Estimated 2% Waste	(23,262)	-	(23,262)	(110,972)	-	(110,972)
7 Estimated Price Variance and 3% Denial	(32,587)	-	(32,587)	(15,751)	-	(15,751)
8 DOH Replenishment	-	(5,421,113)	(5,421,113)	-	(4,234,306)	(4,234,306)
9 Adjustment to Correct Inventory	-	-	-	-	-	-
10 DOH Cost Recovery Admin Charge	(84,517)	-	(84,517)	(86,729)	-	(86,729)
11 Interest Income on Assessments	-	-	-	-	-	-
12 Net Assessment Activity	(802,721)	324,524	(478,196)	(539,185)	865,562	326,377
13 Investment Activity:						
14 Interest and Dividend Income - Morgan Stanley	66,699	-	66,699	48,760	-	48,760
15 Realized Gain/(Loss) on Investments - Morgan Stanley	-	-	-	-	-	-
16 Unrealized Gain/(Loss) on Investments - Morgan Stanley	235,037	-	235,037	(381,705)	-	(381,705)
17 Investment Management Expenses	(9,904)	-	(9,904)	(11,196)	-	(11,196)
18 Interest Income - KeyBank	7,657	-	7,657	307	-	307
19 Net Investment Activity	299,489	-	299,489	(343,834)	-	(343,834)
20 Net Revenues	(503,232)	324,524	(178,708)	(883,019)	865,562	(17,457)

**Washington Vaccine Association
Statement of Activities and Changes in Net Assets**

	A	B	C	D	E	F
	Month Ended January 31, 2023			Month Ended January 31, 2022		
	Administrative	Vaccine Other Expenses	Total	Administrative	Vaccine	Total
21 Administrative Expenses:						
22 Direct Processing Costs						
23 Administrator (Helms & Company, Inc.)	65,432	-	65,432	69,182	-	69,182
24 EDI /ACH Clearinghouse Maintenance (Helms & Company, Inc.)	11,058	-	11,058	7,690	-	7,690
25 Clearinghouse Intake Processing (Avality, Zelis, Etc.)	4,851	-	4,851	1,992	-	1,992
26 Lockbox and Bank Fees	5,394	-	5,394	4,804	-	4,804
27 Recovery and Compliance (Helms & Company, Inc.)	5,250	-	5,250	5,250	-	5,250
28 Lockbox Intake (OrboGraph)	3,750	-	3,750	-	-	-
29 Total Direct Processing Costs	95,734	-	95,734	88,918	-	88,918
30 Executive Director Costs and Related Support Fees						
31 Executive Director Salary	18,810	-	18,810	18,210	-	18,210
32 Payroll Taxes	1,749	-	1,749	4,522	-	4,522
33 Leased Employee per Check Fee	114	-	114	195	-	195
34 Executive Director Travel and Lodging, Education, and Other	1,700	-	1,700	-	-	-
35 Technology Support (Desktop and Telephony)	472	-	472	335	-	335
36 Total Executive Director Costs and Related Support Fees	22,846	-	22,846	23,262	-	23,262
37 Provider and Payer Education and Outreach						
38 Provider Education Materials, Development and Printing	40	-	40	-	-	-
39 Postage	-	-	-	-	-	-
40 Website and Information Technology	-	-	-	405	-	405
41 Technical Consultants	-	-	-	-	-	-
42 Provider Office Training Sessions	-	-	-	-	-	-
43 Advertising and Sponsorships	-	-	-	-	-	-
44 Hospitality	-	-	-	-	-	-
45 Provider Services Rep	-	-	-	-	-	-
46 Leased Employee per Check Fee	-	-	-	-	-	-
47 Total Provider and Payer Education and Outreach	40	-	40	405	-	405
48 Administrative Costs						
49 Legal Counsel	1,604	-	1,604	12,765	-	12,765
50 Audit Fees	-	-	-	-	-	-
51 Government Relations, Including Travel, Meals, and Consultants	-	-	-	-	-	-
52 Registered Agent Fee	-	-	-	-	-	-
53 Bank Fees	-	-	-	-	-	-
54 Office Supplies and Equipment	-	-	-	-	-	-
55 Rent, ELM and Storage Facility	-	-	-	-	-	-
56 Other Admin Support Provided by Lessor	-	-	-	-	-	-
57 Board Retreat and Meetings	-	-	-	-	-	-
58 Insurance						
59 Cyber Liability	19,625	-	19,625	13,355	-	13,355

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

		A	B	C	D	E	F
		Month Ended January 31, 2023			Month Ended January 31, 2022		
		Administrative	Vaccine	Total	Administrative	Vaccine	Total
60	Directors and Officers	-	-	-	-	-	-
61	General Liability	105	-	105	-	-	-
62	Insurance - Other	-	-	-	-	-	-
63	Legal - Special Projects and L	-	-	-	-	-	-
64	Total Administrative Costs	21,334	-	21,334	26,120	-	26,120
65	Other Discretionary Expenditures						
66	Executive Director and Other Contractor Bonus	-	-	-	27,316	-	27,316
67	Human Resources and Governance	3,600	-	3,600	-	-	-
68	Total Other Discretionary Expenditures	3,600	-	3,600	27,316	-	27,316
69	Total Administrative Expenses	143,555	-	143,555	166,021	-	166,021
70	Total Change in Unrestricted Net Assets	\$ (646,786)	\$ 324,524	\$ (322,262)	\$ (1,049,040)	\$ 865,562	\$ (183,477)

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

		For Seven Months Ended January 31, 2023			For Seven Months Ended January 31, 2022		
		A	B	C	D	E	F
		Administrative	Vaccine	Total	Administrative	Vaccine	Total
		Revenues / Vaccine Expenses					
1	Assessment Activity:						
2	Assessments	\$ (4,561,833)	\$ 50,733,264	\$ 46,171,431	\$ (4,255,947)	\$ 50,987,273	\$ 46,731,326
3	Recoveries	351,325	-	351,325	138,973	-	138,973
4	Estimated Over (Under) Collections	-	-	-	-	-	-
5	Refunds	(184,180)	-	(184,180)	(230,564)	-	(230,564)
6	Estimated 2% Waste	(321,003)	-	(321,003)	(931,650)	-	(931,650)
7	Estimated Price Variance and 3% Denial	(133,215)	-	(133,215)	(127,422)	-	(127,422)
8	DOH Replenishment	-	(50,265,020)	(50,265,020)	-	(42,427,513)	(42,427,513)
9	Adjustment to Correct Inventory	-	-	-	-	-	-
10	DOH Cost Recovery Admin Charge	(579,613)	-	(579,613)	(497,225)	-	(497,225)
11	Interest Income on Assessments	-	-	-	-	-	-
12	Net Assessment Activity	(5,428,519)	468,244	(4,960,275)	(5,903,834)	8,559,760	2,655,926
13	Investment Activity:						
14	Interest and Dividend Income - Morgan Stanley	580,225	-	580,225	636,559	-	636,559
15	Realized Gain/(Loss) on Investments - Morgan Stanley	(2,118)	-	(2,118)	12,057	-	12,057
16	Unrealized Gain/(Loss) on Investments - Morgan Stanley	(540,281)	-	(540,281)	(1,213,875)	-	(1,213,875)
17	Investment Management Expenses	(72,194)	-	(72,194)	(83,161)	-	(83,161)
18	Interest Income - KeyBank	64,142	-	64,142	1,360	-	1,360
19	Net Investment Activity	29,774	-	29,774	(647,060)	-	(647,060)
20	Net Revenues	(5,398,744)	468,244	(4,930,500)	(6,550,894)	8,559,760	2,008,866

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

	A	B	C	D	E	F
	For Seven Months Ended January 31, 2023			For Seven Months Ended January 31, 2022		
	Administrative	Vaccine Other Expenses	Total	Administrative	Vaccine	Total
21 Administrative Expenses:						
22 Direct Processing Costs						
23 Administrator (Helms & Company, Inc.)	465,524	-	465,524	484,274	-	484,274
24 EDI /ACH Clearinghouse Maintenance (Helms & Con	52,763	-	52,763	44,924	-	44,924
25 Clearinghouse Intake Processing (Avality, Zelis, Etc.)	36,557	-	36,557	17,139	-	17,139
26 Lockbox and Bank Fees	28,957	-	28,957	27,896	-	27,896
27 Recovery and Compliance (Helms & Company, Inc.)	36,750	-	36,750	36,750	-	36,750
28 Lockbox Intake (OrboGraph)	18,750	-	18,750	-	-	-
29 Total Direct Processing Costs	639,301	-	639,301	610,983	-	610,983
30 Executive Director Costs and Related Support Fees						
31 Executive Director Salary	130,474	-	130,474	123,518	-	123,518
32 Payroll Taxes	6,347	-	6,347	8,061	-	8,061
33 Leased Employee per Check Fee	1,723	-	1,723	1,365	-	1,365
34 Executive Director Travel and Lodging, Education, an	31,451	-	31,451	2,678	-	2,678
35 Technology Support (Desktop and Telephony)	2,845	-	2,845	2,345	-	2,345
36 Total Executive Director Costs and Related Support Fees	172,840	-	172,840	137,967	-	137,967
37 Provider and Payer Education and Outreach						
38 Provider Education Materials, Development and Print	11,877	-	11,877	9,274	-	9,274
39 Postage	-	-	-	40	-	40
40 Website and Information Technology	-	-	-	2,025	-	2,025
41 Technical Consultants	275	-	275	-	-	-
42 Provider Office Training Sessions	-	-	-	715	-	715
43 Advertising and Sponsorships	-	-	-	-	-	-
44 Hospitality	264	-	264	300	-	300
45 Provider Services Rep	-	-	-	-	-	-
46 Leased Employee per Check Fee	-	-	-	-	-	-
47 Total Provider and Payer Education and Outreach	12,416	-	12,416	12,354	-	12,354
48 Administrative Costs						
49 Legal Counsel	27,043	-	27,043	60,416	-	60,416
50 Audit Fees	23,580	-	23,580	15,540	-	15,540
51 Government Relations, Including Travel, Meals, and	-	-	-	-	-	-
52 Registered Agent Fee	-	-	-	-	-	-
53 Bank Fees	-	-	-	-	-	-
54 Office Supplies and Equipment	4,987	-	4,987	1,103	-	1,103
55 Rent, ELM and Storage Facility	-	-	-	-	-	-
56 Other Admin Support Provided by Lessor	-	-	-	-	-	-

Unaudited - For Management Purposes - See Attached Notes
Prepared by Helms And Company, Inc.

Meeting Packet Page 16

Page 12

**Washington Vaccine Association
Statement of Activities and Changes in Net Assets**

		A	B	C	D	E	F
		For Seven Months Ended January 31, 2023			For Seven Months Ended January 31, 2022		
		Administrative	Vaccine	Total	Administrative	Vaccine	Total
57	Board Retreat and Meetings	-	-	-	-	-	-
58	Insurance						
59	Cyber Liability	19,625	-	19,625	13,355	-	13,355
60	Directors and Officers	52,058	-	52,058	47,785	-	47,785
61	General Liability	1,639	-	1,639	1,390	-	1,390
62	Insurance - Other	-	-	-	-	-	-
63	Legal - Special Projects and L	-	-	-	-	-	-
64	Total Administrative Costs	128,932	-	128,932	139,588	-	139,588
65	Other Discretionary Expenditures						
66	Executive Director and Other Contractor Bonus	-	-	-	27,316	-	27,316
67	Human Resources and Governance	30,601	-	30,601	-	-	-
68	Total Other Discretionary Expenditures	30,601	-	30,601	27,316	-	27,316
69	Total Administrative Expenses	984,090	-	984,090	928,208	-	928,208
70	Total Change in Unrestricted Net Assets	\$ (6,382,835)	\$ 468,244	\$ (5,914,590)	\$ (7,479,101)	\$ 8,559,760	\$ 1,080,659

**Washington Vaccine Association
Administrative Budget Status
For Seven Months Ended January 31, 2023**

	A Approved Budget	B Actual January 31, 2023	C Budget Variance
1 Direct Processing Costs			
2 Administrator (Helms & Company, Inc.)	458,024	458,024	-
3 EDI /ACH Clearinghouse Maintenance (Helms & Company, Inc.)	26,250	26,250	-
4 Clearinghouse Intake Processing (Avality, Zelis, Etc.)	21,000	36,557	(15,557)
5 Lockbox and Bank Fees	28,000	28,957	(957)
6 Recovery and Compliance (Helms & Company, Inc.)	36,750	36,750	-
7 Lockbox Intake (OrboGraph)	48,440	52,763	(4,323)
8 Total Direct Processing Costs	618,464	639,301	(20,837)
9 Executive Director Costs and Related Support Fees			
10 Executive Director Salary	128,199	130,474	(2,275)
11 Payroll Taxes	4,937	6,347	(1,410)
12 Leased Employee per Check Fee	1,365	1,723	(358)
13 Executive Director Travel and Lodging, Education, and Other	37,919	31,451	6,468
14 Technology Support (Desktop and Telephony)	2,345	2,845	(500)
15 Total Executive Director Costs and Related Support Fees	174,765	172,840	1,925
16 Provider and Payer Education and Outreach			
17 Provider Education Materials, Development and Printing	43,750	11,877	31,873
18 Postage	8,750	-	8,750
19 Website and Information Technology	8,750	-	8,750
20 Technical Consultants	3,500	275	3,225
21 Provider Office Training Sessions	7,000	-	7,000
22 Advertising and Sponsorships	1,169	-	1,169
23 Hospitality	2,100	264	1,836
24 Provider Services Rep	33,640	-	33,640
25 Leased Employee per Check Fee	-	-	-
26 Total Provider and Payer Education and Outreach	108,659	12,416	96,243
27 Administrative Costs			
28 Legal - General Counsel and Governance	23,331	27,043	(3,712)
29 Audit Fees	22,500	23,580	(1,080)
30 Government Relations Consultants	2,919	-	2,919
31 Registered Agent Fee	150	-	150
32 Investment Management Fees	84,000	72,194	11,806
33 Office Supplies and Equipment	10,150	4,987	5,163
34 Rent	1,050	-	1,050
35 Other Admin Support Provided by Lessor	294	-	294
36 Board Retreat and Meetings	7,000	-	7,000
37 Insurance			-
38 Cyber Liability	16,026	19,625	(3,599)
39 Directors and Officers	52,564	52,058	506
40 General Liability	1,500	1,639	(139)
41 Legal - Special Projects and Litigation	52,500	-	52,500
42 Total Administrative Costs	273,984	201,127	72,857
43 Other Discretionary Expenditures			
44 Executive Director Bonus Pool	49,495	-	49,495
45 Human Resources and Governance	30,450	30,601	(151)
46 Total Other Discretionary Expenditures	79,945	30,601	49,344
47 Total Budget	\$ 1,255,817	\$ 1,056,284	\$ 199,533

**Washington Vaccine Association
Administrative Budget Status
For Month of January 31, 2023**

	A Approved Budget	B Actual January 31, 2023	C Budget Variance
1 Direct Processing Costs			
2 Administrator (Helms & Company, Inc.)	65,432	65,432	-
3 EDI /ACH Clearinghouse Maintenance (Helms & Company, Inc.)	3,750	3,750	-
4 Clearinghouse Intake Processing (Avality, Zelis, Etc.)	3,000	4,851	(1,851)
5 Lockbox and Bank Fees	4,000	5,394	(1,394)
6 Recovery and Compliance (Helms & Company, Inc.)	5,250	5,250	-
7 Lockbox Intake (OrboGraph)	6,920	11,058	(4,138)
8 Total Direct Processing Costs	88,352	95,734	(7,382)
9 Executive Director Costs and Related Support Fees			
10 Executive Director Salary	18,939	18,810	129
11 Payroll Taxes	1,449	1,749	(300)
12 Leased Employee per Check Fee	195	114	81
13 Executive Director Travel and Lodging, Education, and Other	5,417	1,700	3,717
14 Technology Support (Desktop and Telephony)	335	472	(137)
15 Total Executive Director Costs and Related Support Fees	26,335	22,846	3,489
16 Provider and Payer Education and Outreach			
17 Provider Education Materials, Development and Printing	6,250	40	6,210
18 Postage	1,250	-	1,250
19 Website and Information Technology	1,250	-	1,250
20 Technical Consultants	500	-	500
21 Provider Office Training Sessions	1,000	-	1,000
22 Advertising and Sponsorships	167	-	167
23 Hospitality	300	-	300
24 Provider Services Rep	6,728	-	6,728
25 Leased Employee per Check Fee	-	-	-
26 Total Provider and Payer Education and Outreach	17,445	40	17,405
27 Administrative Costs			
28 Legal - General Counsel and Governance	3,333	1,604	1,729
29 Audit Fees	-	-	-
30 Government Relations Consultants	417	-	417
31 Registered Agent Fee	-	-	-
32 Investment Management Fees	12,000	9,904	2,096
33 Office Supplies and Equipment	450	-	450
34 Rent	150	-	150
35 Other Admin Support Provided by Lessor	42	-	42
36 Board Retreat and Meetings	1,000	-	1,000
37 Insurance	-	-	-
38 Cyber Liability	16,026	19,625	(3,599)
39 Directors and Officers	-	-	-
40 General Liability	-	105	(105)
41 Legal - Special Projects and Litigation	7,500	-	7,500
42 Total Administrative Costs	40,918	31,238	9,680
43 Other Discretionary Expenditures			
44 Executive Director Bonus Pool	49,495	-	49,495
45 Human Resources and Governance	4,350	3,600	750
46 Total Other Discretionary Expenditures	53,845	3,600	50,245
47 Total Budget	\$ 226,895	\$ 153,459	\$ 73,436

Washington Vaccine Association

Notes to Financial Statements

For the Seven Months Ended January 31, 2023

Balance Sheet

Lines 2 and 4. Cash decreased in January by approximately \$836,000. Total cash and investments at month end are approximately \$49 million as compared to the budgeted cash position of \$52 million. The time-lag between the date of service and the receipt of payment has been considered when projecting cash reserves for FY2023.

Line 6. The Prepaid Vaccine amount includes the amount requested by the Washington Department of Health (DOH) for the February 2023 replenishment of vaccines. The amount includes the administrative fee of 1.4% which equaled \$82,633 included in the request.

Line 5. Members Estimated Collectible Assessments reflects the value of vaccine funding provided to the DOH for the purchase of vaccines for which the Association expects to receive an assessment payment.

Profit and Loss

Line 2. The amount reported as Assessments includes all assessments received in the month of July. The assessments are tracked in the accounting system using the procedure code and date of service supplied by the provider's remittance advice. While it is assumed that the provider utilized a vaccine that was purchased by the Department of Health in either the corresponding month or a prior month(s), there are too many variables in the purchasing process, the supply chain, and the utilization driving the remittance to provide certainty.

Line 6. The amount reported as 2% Waste is an estimate that was recorded through a journal entry. This estimate will be refined as we continue to process and track the amount of collectible assessments remaining from each DOH funding request. The amount remaining would likely represent vaccines that were not administered and would be considered waste. This will take several months of data before we are able to provide a more accurate estimate and therefore the 2% Waste estimate will continue to be used for the foreseeable future.

Line 7. The amount reported in January as Price Variance and Denials is the actual total of variances and denials identified through the lockbox transactions processed through OrboGraph.

Line 8. The DOH replenishment is the actual "cost" of the vaccines that are associated with the Assessments received in January.

Line 10. The amount reported as DOH Cost Recovery Admin Charge is the amount requested by the DOH for administrative expenses incurred in December. It was paid with the February 2023 replenishment of vaccines.

Other

Based upon a review of detailed assessment remittance data, the Association at times receives both over- and under-payments for remittances. Overpayments are repaid through the refunds process, through balance forward remittances, or through a separate, specific analysis. Utilizing the assessment remittance database, the Association has been able to identify several instances whereby a payer has been incorrectly denying or underpaying assessments for a variety of reasons. The Association's compliance efforts work with payers to resolve these discrepancies and may result in additional assessment revenue or refunds attributable to the current fiscal year that may or may not be related to the current fiscal year.




Ensuring Funds for Childhood Vaccines

2023-24 Vaccine Assessment Grid Development

Presented to the
Washington Vaccine Association
Finance Committee
March 2, 2023

Confidential and Proprietary © 2023




Meeting Packet Page 22

Presentation Overview


1. Process Timeline
2. Approach
3. Administrative Budget Assumptions
4. Model Assumptions Summary
5. 2023-24 Grid

1. 2023-24 Budget & Vaccine Grid Development Process



2. Integrated Approach

1. There is a nested relationship between the administrative budget, the cash flow model, and the vaccine assessment grid
2. Goals of the 2023-24 vaccine grid process include:
 1. Providing grid stability to minimize year-to-year fluctuation
 2. Maintain cash and reserves to a Board-approved level
 3. Ensure reserves for COVID and other new vaccines



3. Administrative Budget Assumptions

Does not
Include
FY2025-26.

WVA Budget Summary	Projected Budgeted Total	Budgeted Total	Budgeted Total	Budgeted Total	FY2024 Assumptions	% Change
	FY 2023	FY 2024	FY 2025	FY 2026		
Direct Processing Costs						
Subtotal	1,060,224	1,146,713	1,146,713	1,146,713	Subtotal % Change	8%
Staff Costs and Related Support Fees						
Subtotal	375,124	434,514	434,514	434,514	Subtotal % Change	16%
Provider and Payer Education and Outreach						
Subtotal	128,600	146,600	146,600	146,600	Subtotal % Change	14%
Administrative Costs						
Subtotal	408,855	396,914	396,914	396,914	Subtotal % Change	-3%
Other Discretionary Expenditures						
Subtotal	101,695	64,904	64,904	64,904	Subtotal % Change	-36%
Total Budget	2,074,498	2,189,645	2,189,645	2,189,645	Total % Change	6%

3. FY24 Administrative Budget Assumptions

- Added Line Items
 - Benefit Stipend
- Deleted Line Items
 - Insurance
- Merged Line Items
 - Salaries
 - Stakeholder Liaison
- Increases/Decreases (+/- 10%)
 - ↑ Administrator
 - ↑ Clearinghouse Fees
 - ↑ Payroll Taxes
 - ↑ Benefit Stipend
 - ↓ PEO Leased Employee Fees
 - ↑ ED Travel, Conferences, Lodging, Education and Other
 - ↑ Technology Support (Desktop and Telephony)

- ↑ Technical Consultants
- ↑ Provider Office Training Sessions
- ↑ Legal, General Counsel and Governance
- ↓ Legal – Special Projects and Litigation
- ↓ Investment Management Fees
- ↓ Office Supplies and Equipment
- ↓ Rent
- ↑ Cyberliability Insurance
- ↑ Board D&O Insurance
- ↑ General Liability Insurance
- ↑ Executive Director Bonus Pool
- ↓ Human Resources and Governance Consultants


Does not Include FY2025-26.

• Past / Future Budget Totals


FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
\$2.027M	\$1.856M	\$2.074M	\$2.189M	\$2.189M	\$2.189M

4. Historical and Model Projections End of FY Cash Balance – FY2017-24

FY 2022 Planning



FY 2023 Planning




4. Expected 2023 Vaccine Assessment Grid Changes

Preliminary.
Updated in
April 2023.


- New Vaccines Added 01/01/2023
 - Priorix (MMR)
 - Vaxneuvance™ (PCV15)
- New Vaccine Expected 07/01/2023
 - PCV20 (Prevnar 20®)
- Changing Presentations Expected 07/02/2023
 - Menveo and Rotarix
- New Vaccines in Pipeline
 - COVID
 - RSV
- COVID Vaccines
 - Bi-Valent 1x / Year
 - Single Dose Vial for Pfizer
 - Blended Price Across Vaccines
- Grid to Be Visually Re-Organized by Vaccine Category

4. Historical and Model Projections End of FY Cash Balance – FY2017-25




Preliminary
Model
Output for
Discussion
03.02.2023.

4. CDC Price Change Over the Previous Year



4. Weighted Average Grid Price Vs. Weighted Average Private Sector Price



Expected Gap to Narrow Slightly in 2024; Updated in April 2023.

Preliminary.
Updated in
April 2023.

4. Model Assumptions Summary

Adjustment Variables	Assumptions			
	FY2023	FY2024	FY2025	FY2026
Assessment Grid as Percent of Prior Year	100%	108%	108%	110%
TRICARE Surcharge (3-Year Lock)	2.5%	2.5%	2.5%	2.5%
DOH Indirect Charge	1.4%	1.4%	1.4%	1.4%
DOH Cost Recovery Fee (2.8% Cap)	1.4%	1.4%	1.4%	1.4%
Vaccine Wastage	2.7%	2.5%	2.4%	2.4%
Denials	13.0%	7.0%	6.0%	5.0%
Denial Recoveries	4.0%	1.0%	1.0%	1.0%
Administrative Budget	\$2.07M	\$2.19M	\$2.19M	\$2.19M
Cash "Burn Down" Amount	\$8.7M (\$11.7M)	\$11.8M	\$8.3M	\$1.5M
Year End Balance	\$46.6M (\$43.3M)	\$31.5M	\$23.2M	\$21.7M
CDC Price Increase	3.6%	3.0%	3.0%	3.0%

4.

WVA Financial Model	Projected Actual				Forecast Period - Absorbs Inflation		
	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Assumptions							
Assessment Grid as Percent of Prior Year					100.0%	103.0%	103.0%
DOH Indirect Charge					1.4%	1.4%	1.4%
DOH Cost Recovery Fee					1.4%	1.4%	1.4%
Vaccine Wastage					2.4%	2.4%	2.4%
Denials					13.0%	11.5%	10.5%
Denial Recoveries					4.0%	3.5%	2.5%
Projected Unknown					15.4%	15.4%	15.4%
Inflows/Outflows							
Assessment Revenue	87,262,137	79,804,611	72,765,986	69,229,085	71,757,578	73,731,650	76,236,545
Vaccine Replenishment	65,491,991	61,491,029	73,662,995	73,549,141	78,881,280	81,461,408	83,905,251
Investment Income	51,903	1,716,186	185,269	(652,934)	-	-	
TRICARE Expense Offset	-				-	-	
Gross Revenue	21,822,049	20,029,769	(711,740)	(4,972,990)	(7,123,702)	(7,729,758)	(7,668,705)
Administrative Cost							
DOH Indirect Charge	-	(1,133,128)	(1,024,831)	(1,029,688)	(1,104,338)	(1,140,838)	(1,140,838)
DOH Cost Recovery Fee	-	(462,339)	(1,049,102)	(889,315)	(1,104,338)	(1,140,838)	(1,140,838)
Vaccine Wastage	-	(1,490,121)	(1,364,228)	(1,575,535)	(1,887,994)	(1,950,222)	(1,955,074)
Denials	-	(8,081,070)	(9,821,218)	(8,999,781)	(8,378,525)	(7,794,442)	(8,028,275)
Denial Recoveries	-		6,507,841	2,138,973	2,552,606	1,855,820	1,911,494
Projected Unknown			11,190,849	15,676,599	11,083,914	11,416,431	11,758,924
Refunds		(467,342)	(372,311)	(375,563)	(349,200)	(349,200)	(349,200)
Administrative Budget	(1,821,862)	(1,986,592)	(1,662,654)	(1,712,271)	(2,051,690)	(2,026,482)	(2,055,724)
Total Administrative Cost	(1,821,862)	(13,620,592)	2,404,346	3,233,420	(1,239,565)	(1,129,773)	(999,531)
Revenue in Excess of Expenditures	20,000,187	6,409,177	1,692,606	(1,739,570)	(8,363,267)	(8,859,531)	(8,668,237)
Effect on Cash Reserves							
Cash Reserves Beginning Balance	34,130,094	50,477,971	56,887,148	58,579,754	56,840,184	48,476,918	39,617,386
Cash Generated/ (Used)	16,347,877	6,409,177	1,692,606	(1,739,570)	(8,363,267)	(8,859,531)	(8,668,237)
Cash Reserves Ending Balance	50,477,971	56,887,148	58,579,754	56,840,184	48,476,918	39,617,386	30,949,150

Preliminary.
Updated in
April 2023.

4. Notes Related to DOH Projections

Slide will be
Updated in
April 2023.

- No new vaccines added for FY23
- Adjustments to periodic changes in VFC fund split
 - No changes from prior year. Federal FY2020 Population Estimates Survey VFC population was 53% and non-VFC eligible is 47%; the non-VFC population includes State privately insured, CHIP and CHP funding sources.
 - DOH will recalculate in the summer of 2022.
- The pandemic's impact on WVA
 - Doses ordered by providers fell and then mostly recovered but remain below pre-pandemic levels
 - DOH's FY22 projections assume about a 5% reduction with recovery in FY23
 - VFC-eligible Medicaid enrollment for Washington children <19 has steadily increased between April 2020 to December 2021
- Unclear when COVID-19 vaccines will no longer be paid for by the Federal government

FY2023 Information

5. 2022-23 Vaccine Grid

Washington Vaccine Association Assessment Grid
FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2022.

For dosage-based assessment (DBA) billing used for commercially insured patients under the age of 19.

Please note that this WVA Assessment Grid, effective July 1, 2022, replaces the grid last updated on July 1, 2021. The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands are determined by the manufacturer and not all brands of flu vaccine are offered through the Childhood Vaccine Program (CVP). **The yellow column is the assessment amount per dose as of July 1, 2022.**

Slide will be Updated in April 2023.

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2021 to 06/30/2022	For Reference: CDC Private Sector Cost/Dose 04/01/2022	WVA Assessment Amount per dose as from 07/01/2022 to 06/30/2023	Percent Change 07/01/2021 to 07/01/2022
90620	58160-0976-20 (10 pack – 1 dose syringe)	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use	Bexsero®	\$120.84	\$201.30	\$120.84	0.0%
90621	00005-0100-10 (10 pack – 1 dose syringe)	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use	Trimeris®	\$115.17			0.0%
90633	58160-0825-11 (10 pack – 1 dose vial)	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use	Havrix®	\$35.87			0.0%
	58160-0825-52 (10 pack – 1 dose syringe)			\$20.72		\$20.72	
	00006-4095-02 (10 pack – 1 dose syringe)		Vaqta®		\$35.61		
90647	00006-4897-00 (10 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use	PedvaxHIB®	\$13.54	\$28.05	\$13.54	0.0%
90648	49281-0545-03 (5 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use	ActHIB®	\$9.46	\$18.24	\$9.46	0.0%
	58160-0818-11 (10 pack – 1 dose vial)		Hiberix®		\$12.00		
90651	00006-4119-03 (10 pack – 1 dose vial)	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use	Gardasil®9	\$189.08	\$253.60	\$189.08	0.0%
	00006-4121-02 (10 pack – 1 dose syringe)						
90670	00005-1971-02 (10 pack – 1 dose syringe)	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	Prevnar 13 TM	\$144.84	\$226.43	\$144.84	0.0%

FY2023 Information
 DRAFT – NOT FOR PUBLICATION

Questions and Discussion